Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation - Wikidata - awgldk - TriplyDB

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

http://www.wikidata.org/entity/Q26825608

about

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.The Michigan Risk Score to Predict Peripherally Inserted Central Catheter-Associated Thrombosis.

P2860

Q36093916-8540185A-F6AA-4ADE-99F3-546CD2257040 Q38630604-62C93601-5FC5-4458-9183-FD90C8E53E58

P2860

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

http://www.wikidata.org/entity/Q26825608

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@ast

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@en

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@nl

type

label

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@ast

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@en

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@nl

prefLabel

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@ast

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@en

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@nl

P1433

Q26825608-430A295C-DA63-4F7B-B10C-A3DF2258C5F0

P1476

Q26825608-219377E1-424F-4FEE-ADE5-B4F897815231

P2093

Q26825608-65F53706-9904-4151-AF8C-DEFBB7A3353A

Q26825608-DDA671EE-B2A4-4BA2-9C29-925A31D54E18

P2860

Q26825608-0AC68177-C8D8-43CB-869F-97E3B1B8434D

Q26825608-1055DC63-1355-4C63-8B15-D7DA313210AF

Q26825608-13C2B27E-2B4C-4358-A8CF-1B787C6D5CF4

Q26825608-14735CCE-29F6-46D1-A690-F058CF1AC6B0

Q26825608-17A5F1B8-E6A5-497C-9C88-61B018682923

Q26825608-1EEC6E9D-754A-4602-AAC2-9307224EA1BE

Q26825608-1EF574BF-1E6F-45BE-88FB-62B4C95CBB7F

Q26825608-2298E827-DD01-49BF-8521-536809B15A36

Q26825608-2876C3A7-3516-470C-AA2D-71D7660ABC5D

Q26825608-2923B6BB-0D41-44FE-8101-7BC274313611

P304

Q26825608-622D9EB8-454B-4B67-9145-42B92D1DFC2E

P31

Q26825608-8D8AB295-0EAA-400C-AAB9-D990E0FA172F

P3181

Q26825608-50F73FBC-385A-4DA8-AF77-21409D9C79D5

P356

Q26825608-EACFFC73-25C3-4971-B25D-71D27DA1569F

P407

Q26825608-FD69CD01-9FA4-49A6-847B-1424A8246652

P433

Q26825608-5EFBE623-5871-40C7-BD7A-7089532E980C

P478

Q26825608-E6F20B5D-E4DE-473E-9267-6BB4108E9750

P50

Q26825608-DCB933CF-2703-433F-ABE5-A5C6D7971091

P577

Q26825608-073E0C9D-23D7-45C1-9702-E26333C97F87

P698

Q26825608-2215738E-7FE1-4E5D-8D47-A9693EA947B9

P921

Q26825608-64D11095-8E25-4AC6-A58C-98C8708DDBC8

Q26825608-DAC71890-8858-4CBD-A181-8EAFEDBBCC24

P932

Q26825608-4F783FCC-E124-47D5-B666-2E20137D1049

P3181

P356

1358863X14566429

P1433

Vascular Medicine

P1476

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation

@en

P2093

Geoffrey D Barnes

http://www.w3.org/2001/XMLSchema#string

James B Froehlich

http://www.w3.org/2001/XMLSchema#string

P2860

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Statins, inflammation and deep vein thrombosis: a systematic review

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

Oral rivaroxaban for symptomatic venous thromboembolism

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

P304

143-152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4326922

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1358863X14566429

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Yogendra Kanthi

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25832602

http://www.w3.org/2001/XMLSchema#string

P921

venous thromboembolism

anticoagulation

P932

4780214

http://www.w3.org/2001/XMLSchema#string